GNC bags Provasca distribution rights

- Last updated on GMT

Related tags: Cardiovascular disease, C-reactive protein, Atherosclerosis, Gnc

GNC Corporation has signed an agreement with Endomatrix for the
distribution of the latter's patented ProVasca with Actothil in the
United States and international markets.

The cardiovascular health supplement is expected to put in its first appearance in GNC stores towards the end of May.

According to Endomatrix​, actothil, Provasca's active component, helps the vascular system maintain its normal, non-inflammatory state.

It said scientific research has shown that people who have a high level of inflammation in their arteries have more risk of developing some form of cardiovascular disease than those with low inflammation, since inflammed are thought to attract LDL 'bad' cholesterol and triglycerides.

"Vascular inflammation and its blood-based biomarker C-reactive Protein ('CRP') are quickly becoming the leading indicators of future cardiovascular events,"​ said Glenn Foley, president and CEO of Santa Rosa, CA-based Endomatrix.

"Provasca with Actothil has been clinically proven to help the body's vascular system to maintain normal levels of C-reactive protein."​Foley expressed his pleasure at working with GNC due to its commitment to consumer education.

More than 100 million American adults are believed to have high cholesterol. But for those whose levels are only 'borderline high' (between 200 - 240 mg/dL) health care professionals are increasingly unwilling to prescribe drugs, which may have potentially harmful side effects. Instead, they encourage patents to lower their cholesterol through diet and exercise rather than prescribing drugs.

Related topics: Suppliers

Related news

Follow us

Featured Events

View more


View more